Viking Fund

The Viking Fund was a venture capital firm based in England that focused on early-stage, technology-based investments, particularly in the Yorkshire and Humber region. Specializing in start-up, early, expansion, and growth stage investments, the fund avoided sectors such as agriculture and fisheries, as well as distressed businesses. It primarily invested in a wide range of industrial sectors, with particular emphasis on information technology, software, medical technology, renewable energy, digital instrumentation, and chemical and pharmaceutical innovation. The fund typically made initial investments ranging from £0.01 million to £0.10 million, with the potential for follow-on investments totaling up to £0.20 million per company. Viking Fund sought to invest alongside private sector investors and aimed to appoint a Non-Executive Director to its portfolio companies. However, the Viking Fund completed its investment activities in 2009 and is no longer operational.

Ian McNeill

Chairman and Founding Partner

2 past transactions

Diurnal

Grant in 2009
Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that focuses on developing hormone therapeutics for chronic endocrine conditions. The company offers Alkindi, a replacement therapy specifically designed for pediatric adrenal insufficiency in Europe. Diurnal is advancing its product pipeline with Chronocort, which has completed Phase III clinical trials for congenital adrenal hyperplasia and adrenal insufficiency. Additionally, its early-stage pipeline includes Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release formulation of T3 for hypothyroidism. Incorporated in 2015, Diurnal aims to provide innovative, high-value therapeutics through proprietary formulations and physiological treatment approaches for rare and chronic diseases.

Cizzle Biotech Ltd.

Venture Round in 2008
Cizzle Biotech Ltd. focuses on the development of CIZ1 gene and its potential as a diagnostic biomarker for the early detection and management of lung cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.